Argus•March 27, 2024

RGNX: Rating increased to a HOLD

Symbols

Sector(s)

Healthcare

Rating

Current Price

$16.19

Price Target

Earnings Estimate

Summary

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level